This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
400
OLN324 by intravitreal injection monthly
Ranibizumab by intravitreal injection monthly
Change in BCVA
Changes in BCVA ETDRS letter score from Day 1 to Week 36
Time frame: Day 1 to Week 36
Mean change in OCT CST
Difference in the mean change from baseline in OCT CST in the Study Eye between the OLN324 arm and the ranibizumab arm
Time frame: Day 1 to Week 12
Change in PED thickness
Difference in the mean change from baseline in PED thickness on OCT in the Study Eye between the OLN324 arm and the ranibizumab arm
Time frame: Day 1 to Week 12
Percentage of participants without retinal fluid in the central subfield at Week 12
Difference in the percentage of participants with absence of both IRF and SRF in the central subfield of the Study Eye between the OLN324 arm and the ranibizumab arm
Time frame: Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.